Cargando…
Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown cause characterised by progressive fibrotic formation in lung tissue. We hypothesise that disrupted metabolic pathways in IPF contribute to disease pathogenesis. METHODS: Metabolomics of human IPF was perform...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531310/ https://www.ncbi.nlm.nih.gov/pubmed/28883924 http://dx.doi.org/10.1136/bmjresp-2017-000183 |
_version_ | 1783253355199463424 |
---|---|
author | Zhao, Yidan D Yin, Li Archer, Stephen Lu, Catherine Zhao, George Yao, Yan Wu, Licun Hsin, Michael Waddell, Thomas K Keshavjee, Shaf Granton, John de Perrot, Marc |
author_facet | Zhao, Yidan D Yin, Li Archer, Stephen Lu, Catherine Zhao, George Yao, Yan Wu, Licun Hsin, Michael Waddell, Thomas K Keshavjee, Shaf Granton, John de Perrot, Marc |
author_sort | Zhao, Yidan D |
collection | PubMed |
description | INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown cause characterised by progressive fibrotic formation in lung tissue. We hypothesise that disrupted metabolic pathways in IPF contribute to disease pathogenesis. METHODS: Metabolomics of human IPF was performed using mass spectroscopy (IPF lung=8; donor lung=8). Gene expression of key metabolic enzymes was measured using microarrays. Of the 108 metabolites whose levels were found altered, 48 were significantly increased, whereas 60 were significantly decreased in IPF samples compared with normal controls. RESULTS: Specific metabolic pathways mediating the IPF remodelling were found with a downregulated sphingolipid metabolic pathway but an upregulated arginine pathway in IPF. In addition, disrupted glycolysis, mitochondrial beta-oxidation and tricarboxylic acid cycle, altered bile acid, haem and glutamate/aspartate metabolism were found in IPF samples compared with control. CONCLUSIONS: Our results show alterations in metabolic pathways for energy consumption during lung structural remodelling, which may contribute to IPF pathogenesis. We believe that this is the first report of simultaneously and systemically measuring changes of metabolites involving nine metabolic pathways in human severe IPF lungs. The measurement of the metabolites may serve in the future diagnosis and prognosis of IPF. |
format | Online Article Text |
id | pubmed-5531310 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-55313102017-09-07 Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study Zhao, Yidan D Yin, Li Archer, Stephen Lu, Catherine Zhao, George Yao, Yan Wu, Licun Hsin, Michael Waddell, Thomas K Keshavjee, Shaf Granton, John de Perrot, Marc BMJ Open Respir Res Interstitial Lung Disease INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a chronic and fatal disease of unknown cause characterised by progressive fibrotic formation in lung tissue. We hypothesise that disrupted metabolic pathways in IPF contribute to disease pathogenesis. METHODS: Metabolomics of human IPF was performed using mass spectroscopy (IPF lung=8; donor lung=8). Gene expression of key metabolic enzymes was measured using microarrays. Of the 108 metabolites whose levels were found altered, 48 were significantly increased, whereas 60 were significantly decreased in IPF samples compared with normal controls. RESULTS: Specific metabolic pathways mediating the IPF remodelling were found with a downregulated sphingolipid metabolic pathway but an upregulated arginine pathway in IPF. In addition, disrupted glycolysis, mitochondrial beta-oxidation and tricarboxylic acid cycle, altered bile acid, haem and glutamate/aspartate metabolism were found in IPF samples compared with control. CONCLUSIONS: Our results show alterations in metabolic pathways for energy consumption during lung structural remodelling, which may contribute to IPF pathogenesis. We believe that this is the first report of simultaneously and systemically measuring changes of metabolites involving nine metabolic pathways in human severe IPF lungs. The measurement of the metabolites may serve in the future diagnosis and prognosis of IPF. BMJ Publishing Group 2017-06-05 /pmc/articles/PMC5531310/ /pubmed/28883924 http://dx.doi.org/10.1136/bmjresp-2017-000183 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Interstitial Lung Disease Zhao, Yidan D Yin, Li Archer, Stephen Lu, Catherine Zhao, George Yao, Yan Wu, Licun Hsin, Michael Waddell, Thomas K Keshavjee, Shaf Granton, John de Perrot, Marc Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
title | Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
title_full | Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
title_fullStr | Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
title_full_unstemmed | Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
title_short | Metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
title_sort | metabolic heterogeneity of idiopathic pulmonary fibrosis: a metabolomic study |
topic | Interstitial Lung Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5531310/ https://www.ncbi.nlm.nih.gov/pubmed/28883924 http://dx.doi.org/10.1136/bmjresp-2017-000183 |
work_keys_str_mv | AT zhaoyidand metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT yinli metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT archerstephen metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT lucatherine metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT zhaogeorge metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT yaoyan metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT wulicun metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT hsinmichael metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT waddellthomask metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT keshavjeeshaf metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT grantonjohn metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy AT deperrotmarc metabolicheterogeneityofidiopathicpulmonaryfibrosisametabolomicstudy |